Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Cannabinoid CB 1 and CB 2 receptors are located at key sites involved in the relaying and processing of noxious inputs. Both CB 1 and CB 2 receptor agonists have analgesic effects in a range of models of inflammatory and neuropathic pain. Importantly, clinical trials of cannabis‐based medicines indicate that the pre‐clinical effects of cannabinoid agonists may translate into therapeutic potential in humans. One of the areas of concern with this pharmacological approach is that CB 1 receptors have a widespread distribution in the brain and that global activation of CB 1 receptors is associated with adverse side effects. Studies of the endogenous cannabinoids (endocannabinoids) have demonstrated that they are present in most tissues and that in some pain states, such as neuropathic pain, levels of endocannabinoids are elevated at key sites involved in pain processing. An alternative approach that can be used to harness the potential therapeutic effects of cannabinoids is to maximise the effects of the endocannabinoids, the actions of which are terminated by re‐uptake and metabolism by various enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) and cyclooxygenase type 2 (COX2). Preventing the metabolism, or uptake, of endocannabinoids elevates levels of these lipid compounds in tissue and produces behavioural analgesia in models of acute pain. Herein we review recent studies of the effects of inhibition of metabolism of endocannabinoids versus uptake of endocannabinoids on nociceptive processing in models of inflammatory and neuropathic pain. British Journal of Pharmacology(2007)152, 624–632; doi:10.1038/sj.bjp.0707433; published online 20 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“The endocannabinoids (ECs), anandamide (AEA; Devane et al., 1992) and 2-arachidonoylglycerol (2AG; Mechoulam et al., 1995; Sugiura et al., 1995) and N-arachidonoyl dopamine (Bisogno et al., 2000; Huang et al., 2002) act at CB1 and CB2 receptors to modulate physiological responses, including…”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 2×
“There is, however, mounting in vitro (Cravatt et al., 1996; Bisogno et al., 1997; Goparaju et al., 1998, 1999; Ueda et al., 1998; Lang et al., 1999; Fowler et al., 2001; Ueda, 2002) and in vivo (Jhaveri et al., 2006; Maione et al., 2006) evidence suggesting the involvement of FAAH in the metabolism…”
BackgroundThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 2×
“cognitive impairment and psychosis (Thomas, 1996; Kalant, 2004; Pacher et al., 2006) arising from their global activation.”
BackgroundBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373 · cited 2×
“The predominant route of catabolism of 2AG is described as being via MAGL, which has a localised distribution in the brain (Dinh et al., 2002).”
BackgroundModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 2×
“Functional effects of inhibition of FAAH in models of pain A number of studies have shown that FAAH is the predominant enzyme responsible for the hydrolysis of AEA (Cravatt et al., 2001; Kathuria et al., 2003; Lichtman et al., 2004; Cravatt and Lichtman, 2004a; Fegley et al., 2005).”
BackgroundAn endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778 · cited 5×
“URB602 has been described as a selective, but low potency, inhibitor of MAGL, which does not alter the catabolism of AEA (Hohmann et al., 2005; see however Vandevoorde et al., 2007).”
BackgroundInfluentialCannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632 · cited 2×
“Another study showed the presence of CB2 receptors on mast cells (Facci et al., 1995); however, when AEA and PEA were tested, only British Journal of Pharmacology (2007) 152 624–632 PEA, which displays little or no activity at cannabinoid receptors, produced a functional response.”
Background
Cited by
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Mechanisms of Acupuncture–Electroacupuncture on Persistent Pain
Zhang, R., Lao, L., Ren, K., & Berman, B. M. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000101 · Cited by 919
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
When does acute pain become chronic?
Voscopoulos, C., & Lema, M. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq323 · Cited by 473
Neugebauer, V., Galhardo, V., Maione, S., & Mackey, S. C. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.014 · Cited by 353
Richardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., Kendall, D. A., Scammell, B. E., Reeve, A. J., & Chapman, V. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2401 · Cited by 303
“The endocannabinoids and PEA are synthesised on demand, and AEA, PEA, and OEA are metabolised predominantly by fatty acid amide hydrolase (FAAH) [22,23].”
BackgroundSelf-citationMoreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Bíró, T., Tóth, B. I., Haskó, G., Paus, R., & Pacher, P. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.004 · Cited by 271
Therapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Telleria-Diaz, A., Schmidt, M., Kreusch, S., Neubert, A.-K., Schache, F., Vazquez, E., Vanegas, H., Schaible, H.-G., & Ebersberger, A. (2010) · Pain · doi:10.1016/j.pain.2009.08.013 · Cited by 109
Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase
Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164806 · Cited by 108
“The endogenous cannabinoid system possesses attractive targets to treat pain related to arthritis and other inflammatory conditions (Holt et al., 2005; Richardson et al., 2008) that include CB1 and CB2 and enzymes responsible for regulating the levels of endogenous cannabinoids.”
BackgroundInfluentialPeripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive
Sasso, O., Wagner, K., Morisseau, C., Inceoglu, B., Hammock, B. D., & Piomelli, D. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.001 · Cited by 68
“Given the demonstrated effect of COX in metabolizing endocannabinoids [51,52] and the potential for the prostamide metabolites of COX to increase neuronal excitability [53], it is possible that this mechanism contributed to the synergy of combined FAAH and sEH inhibitors.”
BackgroundGreco, R., Gasperi, V, Sandrini, G., Bagetta, G., Nappi, G., Maccarrone, M., & Tassorelli, C. (2010) · Cephalalgia · doi:10.1111/j.1468-2982.2009.01924.x · Cited by 64
“Alterations of endocannabinoid levels have been found in animal models of pain, neurological diseases and inflammatory conditions (1,2).”
BackgroundDesroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
“Therefore, endocannabinoid levels in neuropathic pain conditions are consistently reported to be increased at many sites involved in the nociceptive processing (Jhaveri et al., 2007a).”
BackgroundInfluentialGhosh, S., Kinsey, S. G., Liu, Q.-S., Hruba, L., McMahon, L. R., Grim, T. W., Merritt, C. R., Wise, L. E., Abdullah, R. A., Selley, D. E., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.222851 · Cited by 54
“Blockade of either enzyme produces antinociceptive effects in a variety of acute and chronic preclinical models of pain (Kathuria et al., 2003; Chang et al., 2006; Jhaveri et al., 2007; Russo et al., 2007; Kinsey et al., 2009; Spradley et al., 2010; Guindon et al., 2011, 2013; Ghosh et al., 2013).”
BackgroundURB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats
Hasanein, P., Parviz, M., Keshavarz, M., & Roohbakhsh, A. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-026 · Cited by 14
Metadata
- Authors
- Jhaveri, M. D., Richardson, D., & Chapman, V
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 624-632
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1866046632
- Cited by
- 144
- References
- 33
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.